Given the complexity of the immune modulatory response to loss of p53, it is not surprising that reversal of only one part of the response is insufficient to fully regain tumor rejection, since CD11b+ and Treg cell populations remained enriched in p53-null tumors. The gene discussed is ITGAM; the disease is neoplasm.